Taro Pharma (TARO) Reports Q1 Loss of $11.37 on Revenues of $117.6M
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Taro Provides Results for Quarter Ended June 30, 2020
July 29, 2020 5:00 PM EDTQuarter reflects One-Time Charge for Global Resolution with DOJ
HAWTHORNE, N.Y.--(BUSINESS WIRE)-- Taro Pharmaceutical Industries Ltd. (NYSE: TARO) (Taro) today provided unaudited financial results for the quarter ended June 30, 2020.
Quarter ended June 30, 2020 Highlights - compared to Quarter ended June 30, 2019
Net sales of $117.6 million, decreased $43.7 million. Gross profit of $64.9 million decreased $36.8 million, and as a percentage of net sales was 55.2% compared to 63.1%. Research and development expenses of $12.9 million decreased slightly from the prior year. Selling, marketing, general and administrative... More